| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
OBJECTIVE: To determine whether first-trimester exposure to fluoxetine, a selective serotonin reuptake inhibitor commonly used to treat depression and obsessive-compulsive disorders, is associated with increased frequency of fetal malformations. METHODS: We evaluated outcomes of all pregnancies identified prospectively with confirmed first-trimester fluoxetine exposure contained in the Eli Lilly and Company worldwide fluoxetine pregnancy registry. These outcomes were compared with historic reports of newborn surveys. RESULTS: Outcomes were available for 796 pregnancies, 37 from fluoxetine clinical trials and 759 from spontaneous reports. Spontaneous abortions were reported in 110 of the 796 (13.8%) pregnancies. Of the remaining 686, malformations, deformations, and disruptions, including those identified after the perinatal period, were reported in 34 (5.0%). No consistent or recurring pattern of abnormalities was observed. CONCLUSION: Based on comparison with historic reports of newborn surveys, it is unlikely that maternal fluoxetine use during the first trimester of pregnancy results in increased risk of fetal malformations.
This article has been cited by other articles:
|
|
 |
|
  E. Ramos, M. St-Andre, E. Rey, D. Oraichi, and A. Berard Duration of antidepressant use during pregnancy and risk of major congenital malformations The British Journal of Psychiatry, May 1, 2008; 192(5): 344 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Suri, L. Altshuler, G. Hellemann, V. K. Burt, A. Aquino, and J. Mintz Effects of Antenatal Depression and Antidepressant Treatment on Gestational Age at Birth and Risk of Preterm Birth Am J Psychiatry, August 1, 2007; 164(8): 1206 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Malm, T. Klaukka, and P. J. Neuvonen Risks Associated With Selective Serotonin Reuptake Inhibitors in Pregnancy Obstet. Gynecol., December 1, 2005; 106(6): 1289 - 1296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Hemels, A. Einarson, G. Koren, K. L Lanctot, and T. R Einarson Antidepressant Use During Pregnancy and the Rates of Spontaneous Abortions: A Meta-Analysis Ann. Pharmacother., May 1, 2005; 39(5): 803 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Kallen Neonate Characteristics After Maternal Use of Antidepressants in Late Pregnancy Arch Pediatr Adolesc Med, April 1, 2004; 158(4): 312 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Simon, M. L. Cunningham, and R. L. Davis Outcomes of Prenatal Antidepressant Exposure Am J Psychiatry, December 1, 2002; 159(12): 2055 - 2061. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Spigset and B. Mårtensson Fortnightly review: Drug treatment of depression BMJ, May 1, 1999; 318(7192): 1188 - 1191. [Full Text]
|
|
|
|
 |
|
 D. J. Goldstein, K. A. Yonkers, U. Halbreich, C. Brown, T. Pearlstein, W. Harrison, J. Endicott, S. Severino, E. Frank, and B. Parry Use of Serotonin Reuptake Inhibitors by Women of Childbearing Potential JAMA, June 17, 1998; 279(23): 1873 - 1874. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Koren, A. Pastuszak, and S. Ito Drugs in Pregnancy N. Engl. J. Med., April 16, 1998; 338(16): 1128 - 1137. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
